KDR and neoplasm: Considering the prevalence of VEGF and VEGFR-2 in tumor cells and endothelium, as well as the low level of VEGF-induced endocytosis of VEGFR-2 in normal cells compared to tumor cells, it is possible to achieve efficient targeted delivery of nanoparticles to VEGF- and VEGFR-2-positive tumors.